Bioventus Inc. (BVS) is a medical technology company focused on developing and commercializing clinically proven treatments that enhance the body’s natural healing processes.
The company offers a diverse portfolio of products that target musculoskeletal conditions, including bone healing, osteoarthritis, and soft tissue healing. Bioventus is known for its innovative solutions in orthobiologics, which are biologically-based therapies designed to improve the body’s ability to heal itself.
Key products include DUROLANE, a hyaluronic acid injection for joint lubrication in osteoarthritis patients, and EXOGEN, a bone healing system that uses low-intensity pulsed ultrasound to promote the healing of fractures. Bioventus’ growth strategy is centered around expanding its product portfolio, increasing its global footprint, and continuing to invest in research and development to bring new and improved therapies to market.
The company is also focused on strategic acquisitions to complement its existing product lines and enter new therapeutic areas. With a commitment to improving patient outcomes and a strong emphasis on innovation, Bioventus is well-positioned to remain a leader in the orthobiologics and regenerative medicine space.
